Bicycle Therapeutics (BCYC) Receivables - Other (2019 - 2026)

Bicycle Therapeutics has reported Receivables - Other for 8 years, with the latest figure at $40.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 11.44% year-over-year to $40.9 million; the trailing twelve-month figure through Mar 2026 stood at $40.9 million (down 11.44% YoY), and the FY2025 full-year result was $35.6 million, changed 0.15% from the prior year.
• Receivables - Other for Q1 2026 stood at $40.9 million, up from $35.6 million in the prior quarter.
• The five-year high for Receivables - Other was $67.3 million in Q3 2025, with the low at $12.9 million in Q2 2023.
• Historically, Receivables - Other has averaged $37.8 million across 5 years, with a median of $37.4 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Other jumped 260.47% — and 2026, when it decreased 11.44%.
• Bicycle Therapeutics' Receivables - Other stood at $19.2 million in 2022, then climbed by 25.45% to $24.0 million in 2023, then surged by 48.31% to $35.7 million in 2024, then fell by 0.15% to $35.6 million in 2025, then rose by 14.94% to $40.9 million in 2026.
• The last three Receivables - Other figures came in at $40.9 million (Q1 2026), $35.6 million (Q4 2025), and $67.3 million (Q3 2025), per Business Quant data.